Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -4837.99% is 24% below its 5-year average of -3907.28%, around the middle of its 5-year range (-6339.35%–-3148.04%).
2.43% below its 12-month average of -4723.30%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2022 (2022-12-31): -5366.94%.
EBITDA MARGIN
-4837.99%
EBITDA MARGIN AVG TTM
-4723.30%
EBITDA MARGIN AVG 3Y
-4110.91%
EBITDA MARGIN AVG 5Y
-3907.28%
EBITDA MARGIN AVG 10Y
-3980.95%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-2.43%
CURRENT VS 3Y AVG
-17.69%
CURRENT VS 5Y AVG
-23.82%
CURRENT VS 10Y AVG
-21.53%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Imunon, Inc.
Market Cap
$4.94M
EBITDA Margin
-4837.99%
TTM Avg
-4723.30%
3Y Avg
-4110.91%
5Y Avg
-3907.28%
Market Cap
$5.02M
EBITDA Margin
-95.23%
TTM Avg
-128.63%
3Y Avg
-206.76%
5Y Avg
-750.38%
Market Cap
$4.71M
EBITDA Margin
-1127.44%
TTM Avg
-14514.89%
3Y Avg
-11694.21%
5Y Avg
-11694.21%
Market Cap
$5.06M
EBITDA Margin
-8.85%
TTM Avg
9.13%
3Y Avg
18.32%
5Y Avg
18.32%
Market Cap
$5.08M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.67M
EBITDA Margin
-13851.65%
TTM Avg
-8371.58%
3Y Avg
-4777.88%
5Y Avg
-3394.57%
Market Cap
$5.16M
EBITDA Margin
-1670.57%
TTM Avg
-1446.66%
3Y Avg
-2067.25%
5Y Avg
-1679.39%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Imunon, Inc. (IMNN) | $4.94M | -4837.99% | -4723.30% | -4110.91% | -3907.28% |
| Xenetic Biosciences, Inc. (XBIO)vs › | $5.02M | -95.23% | -128.63% | -206.76% | -750.38% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.71M | -1127.44% | -14514.89% | -11694.21% | -11694.21% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.06M | -8.85% | 9.13% | 18.32% | 18.32% |
| CalciMedica, Inc. (CALC)vs › | $4.68M | N/A | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.08M | N/A | N/A | N/A | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.67M | -13851.65% | -8371.58% | -4777.88% | -3394.57% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.16M | -1670.57% | -1446.66% | -2067.25% | -1679.39% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.17M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-4838.0%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2022-12-31 | -5366.94% |
| 2022-09-30 | -4802.37% |
| 2022-06-30 | -4648.24% |
| 2022-03-31 | -4534.39% |
| 2021-12-31 | -4264.55% |
| 2021-09-30 | -3922.11% |
| 2021-06-30 | -3902.56% |
| 2021-03-31 | -4154.20% |
| 2020-12-31 | -3699.52% |
| 2020-09-30 | -3173.22% |
| 2020-06-30 | -3661.07% |
| 2020-03-31 | -3662.10% |
| 2019-12-31 | -3650.57% |
| 2019-09-30 | -4169.87% |
| 2019-06-30 | -4317.23% |
| 2019-03-31 | -3737.37% |
| 2018-12-31 | -3724.02% |
| 2018-09-30 | -3148.04% |
| 2018-06-30 | -6339.35% |
| 2018-03-31 | -3355.15% |
| 2017-12-31 | -3711.82% |
| 2017-09-30 | -3382.05% |
| 2017-06-30 | -3520.17% |
| 2017-03-31 | -3718.30% |
| 2016-12-31 | -3581.31% |
| 2016-09-30 | -4379.78% |
| 2016-06-30 | -3695.04% |
| 2016-03-31 | -4045.46% |
| 2015-12-31 | -3881.24% |
| 2015-09-30 | -3305.79% |
| 2015-06-30 | -4107.73% |
| 2015-03-31 | -5042.70% |
| 2014-12-31 | -5059.39% |
| 2014-09-30 | -5265.13% |
| 2014-06-30 | -5060.46% |
| 2014-03-31 | -4091.72% |
| 2013-12-31 | -2523.13% |
| 2013-09-30 | -2765.51% |
| 2013-06-30 | -3017.14% |
| 2013-03-31 | -3752.02% |
| 2011-03-31 | -176.03% |
